Tango Therapeutics, Inc.
NASDAQ:TNGXBiotechnology
-$3.24 today
- Market cap
- $3.71B
- Beta
- 1.19
- P/E (TTM)
- -38.9
- EPS (TTM)
- -$0.75
Volume 2.75M
Average 3.67M
TNGX Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Tango Therapeutics, Inc.NASDAQ: TNGX
Retained Earnings · Q3 FY2026 · quarter ended Sep 2026
Retained earnings remains negative
Q3 FY2026 retained earnings was -$772.4M, compared with -$564.4M a year earlier.
Context
- Retained earnings amounted to 74.7% of total assets at the end of Q3 FY2026, down 193.9 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -36.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (603.15M) USD
- Year-over-year change
- -20.3%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (603.15M) | -20.3% |
| FY2024 | 2024-12-31 | (501.56M) | -35.1% |
| FY2023 | 2023-12-31 | (371.26M) | -37.8% |
| FY2022 | 2022-12-31 | (269.51M) | -67.1% |
| FY2021 | 2021-12-31 | (161.34M) | — |
Retained Earnings vs competitors
How TNGX compares with its peers on the latest reported figures
- TNGX's Sep 2026 retained earnings of -$772.4M is the 6th highest of the 11 companies compared; the peer median is -$799.45M.
- Its year-over-year change of -36.9% is the 10th highest of 11, against a peer median of -15.4%.
- Retained earnings amounts to 74.7% of total assets for TNGX, versus a peer median of 191.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | -$293.92M | -35.7% | — | 272.6% |
| Aug 2026 | -$630.13M | +31.9% | — | 52.7% | |
| Mar 2026 | -$652.34M | -13.1% | — | 293.6% | |
| Mar 2026 | -$693.45M | -12.6% | — | 579.6% | |
| Mar 2026 | -$763.82M | -15.7% | — | 232.3% | |
| Sep 2026 | -$772.4M | -36.9% | — | 74.7% | |
| Mar 2026 | -$835.08M | -20.2% | — | 81.0% | |
| Sep 2026 | -$1.17B | -35.7% | — | 117.2% | |
| Jun 2026 | -$1.17B | -14.6% | — | 157.5% | |
| Jun 2026 | -$2.17B | -15.2% | — | 224.5% | |
| Jun 2026 | -$3.97B | -80.4% | — | 91.8% | |
| Peer median (excluding TNGX) | -$799.45M | -15.4% | — | 191.0% | |
Competitors are the stored peer set for TNGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 142.75M | 59.97M | 66.39M | 69.53M | 112.28M |
| Short-term Investments | 342.51M | 306.17M | 270.5M | 188.39M | 230.86M |
| Net Receivables | 2M | 2M | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 567K | 7.14M | 9.65M | 8.43M | 10.62M |
| Total Current Assets | 492.34M | 375.27M | 346.54M | 266.34M | 353.76M |
| Property, Plant & Equipment (Net) | 6.09M | 57.77M | 53.42M | 47.58M | 42.49M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.73M | 3.43M | 2.61M | 2.57M | 2.44M |
| Total Non-current Assets | 7.82M | 61.2M | 56.03M | 50.15M | 44.93M |
| Total Assets | 500.16M | 436.47M | 402.57M | 316.49M | 398.69M |
| Account Payables | 3.23M | 4.45M | 2.79M | 1.6M | 1.18M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 52K | 35K | 0 | 0 | 0 |
| Deferred Revenue | 26.02M | 31.79M | 25.67M | 17.62M | 0 |
| Other Current Liabilities | 666K | 1.27M | 7.49M | 1.74M | 1.29M |
| Total Current Liabilities | 40.69M | 55.55M | 45.94M | 38.17M | 21.68M |
| Long-term Debt | 0 | 0 | 0 | 0 | 30.83M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 114.72M | 92.09M | 66.68M | 44.77M | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 114.72M | 131.45M | 103.52M | 78.81M | 30.83M |
| Total Liabilities | 155.41M | 186.99M | 149.46M | 116.98M | 52.51M |
| Common Stock | 88K | 88K | 102K | 108K | 136K |
| Retained Earnings | (161.34M) | (269.51M) | (371.26M) | (501.56M) | (603.15M) |
| Accumulated OCI | (765K) | (3.71M) | 186K | 336K | 224K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 344.75M | 249.48M | 253.11M | 199.52M | 346.18M |
| Total Debt | 1.5M | 41.13M | 38.92M | 36.49M | 33.57M |
| Net Debt | (141.24M) | (18.84M) | (27.47M) | (33.04M) | (78.71M) |
Tango Therapeutics, Inc.
NASDAQ:TNGX
Intrinsic Alpha fair value
Locked
Current Price
$21.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.